Translesion synthesis polymerase inhibitors and uses thereof
AssigneeUniversity of Vermont and State Agricultural College
InventorNimrat Chatterjee
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods relating to the inhibitors of the translesion synthesis (TLS) pathway, including methods of preventing or treating RNA viruses and prolonged symptoms (for example, long COVID).
Claims38
A method of treating a viral infection in a subject, wherein the method comprises administering to the subject an inhibitor of the translesion synthesis (TLS) pathway.
The method of any one of the preceding claims, wherein the viral infection is caused by an RNA virus.
The method of any of the preceding claims, wherein the subject is administered the inhibitor by oral administration or intravenous administration.
A pharmaceutical composition suitable for treating a viral infection in a subject, wherein the pharmaceutical composition comprises an inhibitor of the translesion synthesis (TLS) pathway.
The pharmaceutical composition of 33, wherein the subject has at least one of:
- cardiomyopathy, neurological issues, diabetes, aging, respiratory system disorders, nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, gastrointestinal disorders, musculoskeletal pain, anemia, headaches, shortness of breath, anosmia, parosmia, muscle weakness, and low fever.
Dependencies are inferred from the claim text.